1.Kasuwancin faɗaɗawa: Yuyue likitan sake siye, 100% riƙe
Kwanan nan, aikace-aikacen rajistan kasuwancin ya nuna cewa Jiangsu Lerun lens Co., Ltd. ya sami sauye-sauyen masana'antu da kasuwanci, masu hannun jari na asali Jiangsu Hongyi Garden Construction Engineering Co., Ltd. da Danyang xintongqiu Optical Glasses Co., Ltd. sun janye, kuma sabon mai hannun jari Yuyue medical (002223) yana riƙe da 100%.Ya kamata a bayyana cewa, a farkon shekarar 2019, Yuyue ya kashe kusan yuan miliyan 80 wajen mallakar kamfanonin sarrafa ido guda biyu.
2.A ranar 24 ga Mayu, gidan yanar gizon hukuma na Cibiyar Siyar da Injin Magunguna ta Zhejiang ta fitar da sanarwa kan darajar adadin wuraren ajiyar magunguna a cikin 2021, kuma an sanar da bayanan da suka dace na manyan samfuran 200 a hukumance.Top10 ya mamaye manyan kamfanonin harhada magunguna na kasa da kasa, da allunan clopidogrel bisulfate daga rukunin magunguna na China Stone Pharmaceutical da Turai Italiya Pharmaceutical Co., Ltd., wani kamfani na magunguna na cikin gida, ya mamaye Top11.
3.A cikin jerin tsare-tsare, sabbin magunguna na cikin gida sun haifar da babban lokacin girbi, kuma kamfanonin harhada magunguna sun shiga cikin lokacin musayar nasara.Dangane da bayanan micnet, tun daga 2011, kusan 90 na gida 1 sabbin magunguna (ciki har da aji 1 da 1.1, ban da alluran rigakafi, iri ɗaya a ƙasa) an amince da su don jeri, kuma kamfanonin harhada magunguna 15 sun amince da nau'ikan 2 ko fiye.Fa'idodin manyan kantin magani na gargajiya sun shahara, kuma Hengrui yana da ƙarfi a farkon wuri.Bayan hauhawa, shugaban fasahar kere-kere ba ya son a yi gaba, kuma Baiji Shenzhou, Hehuang Pharmaceutical da zaiding sun kasance a matsayi na uku.
4.Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., wani reshen Guangzhou Pharmaceutical Group, daya daga cikin manyan kamfanoni 500 na duniya, ya sanar a yammacin ranar 30 ga Mayu cewa, masana'antar sarrafa magunguna ta Baiyunshan ta sami wasika daga FDA ta Amurka (watau Hukumar Abinci ta Amurka). da Gudanar da Magunguna) a ranar 29 ga Mayu, amincewa da allunan bys10 da za a yi amfani da su a gwaji na asibiti don maganin ci-gaban ciwace-ciwacen ciwace tare da haɗin RET ko maye gurbi.Baiyunshan Pharmaceutical General Factory yana shirin gudanar da buɗaɗɗen, gwaji na asibiti da yawa na sabon magani don alamun da ke sama lokacin da yanayi ya cika nan gaba.
5.Kasuwancin wakilcin bambanci yana sake bunƙasa.Kelun Pharmaceutical ya lashe na farko kwaikwayo da Hengrui magani don zuwa teku.Bisa kididdigar da aka yi a Intanet, a shekarar 2021, yawan tallace-tallacen da aka yi a cibiyoyin kiwon lafiya na jama'a a kasar Sin ya zarce yuan biliyan 17, wanda ya karu da kashi 13.05% a duk shekara;Hengrui Pharmaceutical, General Electric Pharmaceutical da Yangtze River Pharmaceutical sun kasance a cikin manyan uku;Adadin tallace-tallace na samfurori biyar ya zarce yuan biliyan 1, wanda allurar iodixanol ke jagoranta.A halin yanzu, 10 nau'ikan wakilan wakilan (iodophor ya sadu da yanayin tarin tarin kudaden;Nau'in Timplealibai na TimplatS (Bayanai na Samfurin 23) suna kan kasuwa don bincika, kuma ku kasance farkon magoya bayan su yi koyi da su.
6.A ranar 7 ga watan Yuni, kamfanin Huiyu Pharmaceutical ya sanar da cewa, mallakarsa gaba dayanta na kamfanin samar da magunguna na Seacross, ta allurar prosafel, ta samu amincewar yin rajista a kasar Birtaniya, wanda ya zama kamfani na farko da ya samu amincewar maganin na yau da kullum a Burtaniya.Tun daga wannan shekarar, an amince da kayayyakin alluran magunguna na Huiyu a gida da waje.
7.200 na farko kwaikwayo za a yarda!Abubuwan kwaikwayi masu zafi na manyan kamfanoni sun fallasa.
A cikin 'yan shekarun nan, an ƙarfafa magunguna na farko a matakin ƙasa.Yayin da ake rarraba sabbin magunguna, manyan kamfanonin harhada magunguna tare da babban matakin R&D suma sun hanzarta aikin “kwaikwayo”.Tun daga 2018, an sami samfuran kusan 200 waɗanda aka yi amfani da su don lissafin kwaikwayi kuma ana yin nazari, kuma ba a sami amincewar gida don samfuran iri ɗaya ba.Ana sa ran za a amince da su don jeri bayan 2022, tare da saman zafi biliyan ɗari biyar.
8.Humanwell yana nuna ƙarfinsa!Sabbin magunguna aji 20 da ingantattun magunguna guda 18 sun yi zafi.
A cikin 'yan shekarun nan, likitancin ɗan adam, jagoran maganin sa barci da kwantar da hankali, ya ci gaba da ingantawa da ƙarfafa ainihin gasa ta hanyar "mayar da hankali, ƙididdiga da ƙaddamarwa".Kwanan nan, kamfanin ya sanar da cewa, zai kashe fiye da yuan biliyan 1.6 wajen siyan kadarorin kadarori domin hada albarkatun cikin gida da fadada karfinsa.Daga cikin su, za a yi amfani da kadarorin kadarorin da cibiyar bincike da ci gaba na magunguna ta siya a matsayin tushen “jama’ar kasuwanci da kirkire-kirkire” don haɓaka shimfidar ƙima.A cikin rabin farko na 2022, kamfanin yana da ƙarin sabbin magungunan aji 1 guda biyu da aka amince da su don amfani da asibiti, kuma sabon ingantaccen magani na farko yana garzayawa zuwa kasuwa.Kwaikwayo na farko na allunan chlorbazam na yara masu nauyi shima ya ja hankali sosai.Bugu da kari, manyan kayayyaki guda uku suna gab da haduwa da rukuni na bakwai na saye na kasa.
9.Zhengda sunny!Sabbin magungunan aji 58 da 9 na farko na kwaikwayi.
Kwanan nan, layin samfurin na Zhengda Tianqing Pharmaceutical ya sami sabon ci gaba: samar da tq-b3101 capsule, sabon nau'in maganin ciwon daji na aji 1, an ba da rahoton cewa, an amince da allurar sophopovir na gida ta uku, da allura tqc2938, sabon aji 1. An yarda da maganin asma, don amfani da asibiti A halin yanzu, Zhengda Tianqing Pharmaceutical Co., Ltd. yana da sabbin magunguna 73 (sababbin magunguna na aji 58) a cikin matakin aikace-aikacen asibiti ko sama, wanda sabbin magunguna 14 (sabbin aji 5 na 1) kwayoyi) suna cikin mataki na III ko sama, kuma ana sa ran jerin;Dangane da magunguna na generic, nau'ikan 54 an kimanta (21 sune farko na farko), an haɗa magunguna 8 na siye na bakwai, da kuma tsofaffi suna da rajista, wanda ba a amince da su ba karo na farko (ciki har da kwafin farko na nau'in sashi).
JinDun Medicalyana da haɗin gwiwar bincike na kimiyya na dogon lokaci tare da fasahar kere-kere tare da jami'o'in kasar Sin.Tare da wadataccen albarkatun kiwon lafiya na Jiangsu, tana da dangantakar kasuwanci ta dogon lokaci tare da Indiya, kudu maso gabashin Asiya, Koriya ta Kudu, Japan da sauran kasuwanni.Hakanan yana ba da sabis na kasuwa da tallace-tallace a cikin gabaɗayan tsari daga matsakaici zuwa ƙãre samfurin API.Yi amfani da tarin albarkatun Yangshi Chemical a cikin sinadarai na fluorine don samarwasabis na gyare-gyaren sinadarai na musammanga abokan tarayya.Samar da sabbin abubuwa da ayyukan bincike na ƙazanta don ƙaddamar da abokan ciniki.
Lokacin aikawa: Nuwamba-09-2022